133 related articles for article (PubMed ID: 24479809)
1. Regulation of KRAS-PAK4 axis by microRNAs in cancer.
Choudhry ZS; Tripathi V; Sutton M; Bao B; Mohammad RM; Azmi AS
Curr Pharm Des; 2014; 20(33):5275-8. PubMed ID: 24479809
[TBL] [Abstract][Full Text] [Related]
2. Targeting PAK4 Inhibits Ras-Mediated Signaling and Multiple Oncogenic Pathways in High-Risk Rhabdomyosarcoma.
Dasgupta A; Sierra L; Tsang SV; Kurenbekova L; Patel T; Rajapakse K; Shuck RL; Rainusso N; Landesman Y; Unger T; Coarfa C; Yustein JT
Cancer Res; 2021 Jan; 81(1):199-212. PubMed ID: 33168646
[TBL] [Abstract][Full Text] [Related]
3. p21-activated kinase 4: a druggable target in the elusive oncogenic KRAS pathway?
Azmi AS; Mohammad RM
Future Med Chem; 2015; 7(1):5-7. PubMed ID: 25582328
[No Abstract] [Full Text] [Related]
4. Knockdown of PAK4 or PAK1 inhibits the proliferation of mutant KRAS colon cancer cells independently of RAF/MEK/ERK and PI3K/AKT signaling.
Tabusa H; Brooks T; Massey AJ
Mol Cancer Res; 2013 Feb; 11(2):109-21. PubMed ID: 23233484
[TBL] [Abstract][Full Text] [Related]
5. P21-activated kinase 4--not just one of the PAK.
Dart AE; Wells CM
Eur J Cell Biol; 2013; 92(4-5):129-38. PubMed ID: 23642861
[TBL] [Abstract][Full Text] [Related]
6. Targeting Rho GTPase effector p21 activated kinase 4 (PAK4) suppresses p-Bad-microRNA drug resistance axis leading to inhibition of pancreatic ductal adenocarcinoma proliferation.
Mohammad RM; Li Y; Muqbil I; Aboukameel A; Senapedis W; Baloglu E; Landesman Y; Philip PA; Azmi AS
Small GTPases; 2019 Sep; 10(5):367-377. PubMed ID: 28641032
[TBL] [Abstract][Full Text] [Related]
7. P21 activated kinase signaling in cancer.
Rane CK; Minden A
Semin Cancer Biol; 2019 Feb; 54():40-49. PubMed ID: 29330094
[TBL] [Abstract][Full Text] [Related]
8. PAK4 interacts with p85 alpha: implications for pancreatic cancer cell migration.
King H; Thillai K; Whale A; Arumugam P; Eldaly H; Kocher HM; Wells CM
Sci Rep; 2017 Feb; 7():42575. PubMed ID: 28205613
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-433 inhibits cell proliferation in hepatocellular carcinoma by targeting p21 activated kinase (PAK4).
Xue J; Chen LZ; Li ZZ; Hu YY; Yan SP; Liu LY
Mol Cell Biochem; 2015 Jan; 399(1-2):77-86. PubMed ID: 25410752
[TBL] [Abstract][Full Text] [Related]
10. N-terminal interaction domain implicates PAK4 in translational regulation and reveals novel cellular localization signals.
Baldassa S; Calogero AM; Colombo G; Zippel R; Gnesutta N
J Cell Physiol; 2010 Sep; 224(3):722-33. PubMed ID: 20578242
[TBL] [Abstract][Full Text] [Related]
11. PAK4 in cancer development: Emerging player and therapeutic opportunities.
Yuan Y; Zhang H; Li D; Li Y; Lin F; Wang Y; Song H; Liu X; Li F; Zhang J
Cancer Lett; 2022 Oct; 545():215813. PubMed ID: 35798086
[TBL] [Abstract][Full Text] [Related]
12. CDC42 binds PAK4 via an extended GTPase-effector interface.
Ha BH; Boggon TJ
Proc Natl Acad Sci U S A; 2018 Jan; 115(3):531-536. PubMed ID: 29295922
[TBL] [Abstract][Full Text] [Related]
13. LCH-7749944, a novel and potent p21-activated kinase 4 inhibitor, suppresses proliferation and invasion in human gastric cancer cells.
Zhang J; Wang J; Guo Q; Wang Y; Zhou Y; Peng H; Cheng M; Zhao D; Li F
Cancer Lett; 2012 Apr; 317(1):24-32. PubMed ID: 22085492
[TBL] [Abstract][Full Text] [Related]
14. Strategy and validation of a structure-based method for the discovery of selective inhibitors of PAK isoforms and the evaluation of their anti-cancer activity.
Song PL; Wang G; Su Y; Wang HX; Wang J; Li F; Cheng MS
Bioorg Chem; 2019 Oct; 91():103168. PubMed ID: 31400553
[TBL] [Abstract][Full Text] [Related]
15. Zic2 promotes tumor growth and metastasis via PAK4 in hepatocellular carcinoma.
Lu SX; Zhang CZ; Luo RZ; Wang CH; Liu LL; Fu J; Zhang L; Wang H; Xie D; Yun JP
Cancer Lett; 2017 Aug; 402():71-80. PubMed ID: 28577975
[TBL] [Abstract][Full Text] [Related]
16. PAK4 signaling in health and disease: defining the PAK4-CREB axis.
Won SY; Park JJ; Shin EY; Kim EG
Exp Mol Med; 2019 Feb; 51(2):1-9. PubMed ID: 30755582
[TBL] [Abstract][Full Text] [Related]
17. Differential role for PAK1 and PAK4 during the invadopodia lifecycle.
Nicholas NS; Pipili A; Lesjak MS; Wells CM
Small GTPases; 2019 Jul; 10(4):289-295. PubMed ID: 28301299
[TBL] [Abstract][Full Text] [Related]
18. PAK4 is required for regulation of the cell-cycle regulatory protein p21, and for control of cell-cycle progression.
Nekrasova T; Minden A
J Cell Biochem; 2011 Jul; 112(7):1795-806. PubMed ID: 21381077
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-mediated regulation of KRAS in cancer.
Kim M; Slack FJ
J Hematol Oncol; 2014 Nov; 7():84. PubMed ID: 25433809
[TBL] [Abstract][Full Text] [Related]
20. MiR-199a/b-3p inhibits gastric cancer cell proliferation via down-regulating PAK4/MEK/ERK signaling pathway.
Zeng B; Shi W; Tan G
BMC Cancer; 2018 Jan; 18(1):34. PubMed ID: 29304764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
